STANTON PARK GROUP

Lobbying for KYOWA KIRIN · Pharmaceutical Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $45,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Pharmacy

FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to Newborn Screening and Genetic Testing;

Trade (domestic/foreign)

Issues Related to Trade

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.